Shudong Wang

发表

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

Peter M Fischer, Wayne Jackson, Campbell McInnes, 2010, Chemistry & biology.

Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.

Shudong Wang, N. Portman, Sarah Alexandrou, 2019, Endocrine-related cancer.

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)

Nikolai Zhelev, Shudong Wang, D. Zheleva, 2002, International journal of cancer.

Discovery of CDK5 Inhibitors through Structure-Guided Approach.

Sunita K. C. Basnet, Shudong Wang, N. Khair, 2019, ACS medicinal chemistry letters.

In Vitro Antitumor Mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide

C. Laughton, Shudong Wang, Tiangong Lu, 2015, Molecular Pharmacology.

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells

Sunita K. C. Basnet, Shudong Wang, P. Li, 2016, Oncotarget.

Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop.

Su-Ying Wu, P. Taylor, D. Lane, 2003, Structure.

Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors.

Weiliang Zhu, Kaixian Chen, Hualiang Jiang, 2011, Journal of medicinal chemistry.

2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.

A. Osnowski, Su-Ying Wu, M. Walkinshaw, 2004, Journal of medicinal chemistry.

Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin.

P. Fischer, Shudong Wang, N. Zhelev, 2006, Bioorganic & medicinal chemistry letters.

Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.

Peter M Fischer, Darren Gibson, Campbell McInnes, 2006, Chemistry & biology.

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.

W. Tilley, Shudong Wang, S. Tadesse, 2018, Journal of medicinal chemistry.

Synthesis and biological evaluation of benzo[d]imidazole derivatives as potential anti-cancer agents.

Shudong Wang, H. Alkahtani, A. Abbas, 2012, Bioorganic & medicinal chemistry letters.

Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy.

Shudong Wang, P. Li, C. Prestidge, 2016, Molecular pharmaceutics.

Targeting CDK2 in cancer: challenges and opportunities for therapy.

W. Tilley, Shudong Wang, N. Portman, 2019, Drug discovery today.

Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.

P. Fischer, Shudong Wang, F. Lam, 2021, European journal of medicinal chemistry.

Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.

Sunita K. C. Basnet, Aleksandra M Ochnik, Shudong Wang, 2021, European journal of medicinal chemistry.

Targeting CDK9 for treatment of colorectal cancer

C. Ricciardelli, N. Lokman, Shudong Wang, 2019, Molecular Oncology.

Targeting CDK9 for treatment of colorectal cancer

C. Ricciardelli, N. Lokman, Shudong Wang, 2019, Molecular oncology.

Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.

Sunita K. C. Basnet, Shudong Wang, P. Li, 2017, European journal of medicinal chemistry.

Unveiling new chemical scaffolds as Mnk inhibitors.

Sunita K. C. Basnet, Shudong Wang, P. Li, 2016, Future medicinal chemistry.

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

C. Fegan, P. Fischer, Shudong Wang, 2013, Oncotarget.

Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73

Yi Chen, P. Fischer, Jian Ding, 2014, Oncotarget.

Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.

P. Fischer, Shudong Wang, Xiangrui Liu, 2013, European journal of medicinal chemistry.

Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents.

Shudong Wang, Xiangrui Liu, F. Lam, 2012, European journal of medicinal chemistry.

In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83

P. Fischer, Shudong Wang, Xiangrui Liu, 2012, Investigational New Drugs.

Insights into the Importance of DFD-Motif and Insertion I1 in Stabilizing the DFD-Out Conformation of Mnk2 Kinase.

Shudong Wang, M. Sykes, Jinqiang Hou, 2013, ACS medicinal chemistry letters.

Synthesis and biological evaluation of heteroaryl styryl sulfone derivatives as anticancer agents.

Shudong Wang, P. Li, Malika Kumarasiri, 2016, Bioorganic & medicinal chemistry letters.

Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.

Shudong Wang, F. Lam, M. Sykes, 2015, Cancer letters.

An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.

Sunita K. C. Basnet, Shudong Wang, Malika Kumarasiri, 2015, European journal of medicinal chemistry.

New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships.

P. Fischer, Shudong Wang, M. Hajdúch, 2003, Journal of medicinal chemistry.

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

Shudong Wang, F. Lam, R. Milne, 2018, Investigational New Drugs.

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?

Shudong Wang, Sarah Diab, Mingfeng Yu, 2020, Journal of medicinal chemistry.

Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia.

R. Prinjha, R. D'Andrea, I. Lewis, 2020, Blood advances.

The synergistic effect of combined P-TEFb and EGFR inhibition on triple-negative breast cancer

J. Foekens, M. Smid, Yinghui Zhang, 2022 .

Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells

Shudong Wang, Malika Kumarasiri, S. Islam, 2022, Pharmaceuticals.

Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2

Sunita K. C. Basnet, Shudong Wang, Sarah Diab, 2015, Molecular Pharmacology.

A combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma.

P. Hersey, H. Tseng, Shudong Wang, 2021, The Journal of investigative dermatology.

Discovery of N-phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine derivatives as potent Mnk2 inhibitors: design, synthesis, SAR analysis, and evaluation of in vitro anti-leukaemic activity.

Sunita K. C. Basnet, Shudong Wang, Laychiluh B Mekonnen, 2019, Medicinal chemistry (Shariqah (United Arab Emirates)).

Targeting Pim kinases for cancer treatment: opportunities and challenges.

Shudong Wang, Malika Kumarasiri, M. Sykes, 2015, Future medicinal chemistry.

Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities

M. Noble, J. Endicott, P. Fischer, 2013, Journal of medicinal chemistry.

Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.

Peter M Fischer, Wayne Jackson, Campbell McInnes, 2010, Journal of medicinal chemistry.

Synthesis and Evaluation of 5-Chloro-2-Methoxy-N-(4-Sulphamoylphenyl) Benzamide Derivatives as Anti-cancer Agents

K. Abouzid, Shudong Wang, A. Abdelaziz, 2015 .

Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.

M. Walkinshaw, C. Midgley, P. Fischer, 2004, Bioorganic & medicinal chemistry letters.

Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists.

Shane M. Wilkinson, M. Kassiou, Shudong Wang, 2017, European journal of medicinal chemistry.

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

Shudong Wang, H. Albrecht, R. Milne, 2021, Frontiers in Oncology.

ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities

Shudong Wang, F. Lam, T. Bradshaw, 2012, Investigational New Drugs.

Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3H)‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation

Sunita K. C. Basnet, Shudong Wang, P. Li, 2014, ChemMedChem.

Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities.

C. Midgley, Shudong Wang, Xiangrui Liu, 2014, Journal of Medicinal Chemistry.

US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy

Shudong Wang, Mingfeng Yu, S. Tadesse, 2021 .

Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin‐dependent kinases 4 and 6 as anticancer agents

Shudong Wang, F. Lam, Malika Kumarasiri, 2018, British journal of pharmacology.

A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors.

M. Brown, Shudong Wang, J. Lenjisa, 2017, Future medicinal chemistry.

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.

Sunita K. C. Basnet, Shudong Wang, F. Lam, 2017, Journal of medicinal chemistry.

Targeting CDK6 in cancer: State of the art and new insights

Shudong Wang, Malika Kumarasiri, Mingfeng Yu, 2015, Cell cycle.

Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.

D. Lane, R. Jackson, D. Zheleva, 2010, Journal of medicinal chemistry.

Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma

W. Weichert, U. Dirksen, B. Schäfer, 2020, Cancers.

A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.

C. Ricciardelli, N. Lokman, Shudong Wang, 2020, Gynecologic oncology.

Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.

Shudong Wang, Laychiluh B Mekonnen, Manjun Li, 2021, European journal of medicinal chemistry.

Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition

Shudong Wang, Mingfeng Yu, S. Islam, 2023, Cancers.

CDK12: a potential therapeutic target in cancer.

Shudong Wang, F. Emadi, Theodosia Teo, 2020, Drug discovery today.

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia

Theodosia Teo, Mingfeng Yu, Sunita K. C. Basnet, 2015, Molecular Pharmacology.

CDK5 in oncology: recent advances and future prospects.

Shudong Wang, N. Khair, J. Lenjisa, 2017, Future medicinal chemistry.

Targeting Mnks for Cancer Therapy

C. Proud, Shudong Wang, F. Lam, 2012, Oncotarget.

Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?

Shudong Wang, Malika Kumarasiri, Mingfeng Yu, 2018, Journal of medicinal chemistry.

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.

Peter M Fischer, Shudong Wang, P. Fischer, 2008, Trends in pharmacological sciences.

Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target

Jennifer H. Martin, Shudong Wang, S. Islam, 2021, British journal of clinical pharmacology.

MAP kinase-interacting kinases--emerging targets against cancer.

C. Proud, Shudong Wang, Malika Kumarasiri, 2014, Chemistry & biology.

In Search of Novel CDK8 Inhibitors by Virtual Screening

Peng Wang, Shudong Wang, Malika Kumarasiri, 2017, J. Chem. Inf. Model..

Targeting CDK9: a promising therapeutic opportunity in prostate cancer.

Shudong Wang, Malika Kumarasiri, Laychiluh B Mekonnen, 2016, Endocrine-related cancer.

Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity

M. Noble, J. Endicott, P. Fischer, 2012, Journal of medicinal chemistry.

CDKI-73 Is a Novel Pharmacological Inhibitor of Rab11 Cargo Delivery and Innate Immune Secretion

Shudong Wang, D. Brooks, E. Parkinson-Lawrence, 2020, Cells.

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia

Sunita K. C. Basnet, Shudong Wang, J. Lenjisa, 2022, Cancers.

CDKI‐71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol

P. Fischer, Shudong Wang, Xiangrui Liu, 2012, International journal of cancer.

Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors.

C. Midgley, Shudong Wang, F. Lam, 2011, Bioorganic & medicinal chemistry letters.

Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.

Shudong Wang, Mingfeng Yu, Yuchao Yang, 2022, Journal of medicinal chemistry.

A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner

J. Baell, G. McArthur, Xu Dong Zhang, 2016, Oncotarget.

Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies.

Shudong Wang, J. Lenjisa, Laychiluh B Mekonnen, 2023, Drug discovery today.

Enabling Oral SN38-Based Chemotherapy with a Combined Lipophilic Prodrug and Self-Microemulsifying Drug Delivery System.

Shudong Wang, C. Prestidge, Shasha Rao, 2016, Molecular pharmaceutics.

Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.

Shudong Wang, Shangren Chen, Xinliang Pan, 2017, Biochemical and biophysical research communications.

Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.

Sunita K. C. Basnet, Shudong Wang, Manjun Li, 2019, Bioorganic & medicinal chemistry letters.

Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer

P. Fischer, Shudong Wang, S. McClue, 2001 .

Discovery of Potent Inhibitors of Cyclin‐Dependent Kinases 7 and 9: Design, Synthesis, Structure‐Activity Relationship Analysis and Biological Evaluation

Sunita K. C. Basnet, Shudong Wang, Laychiluh B Mekonnen, 2023 .

Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.

D. Lane, P. Fischer, Shudong Wang, 2004, Chemistry & biology.

Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells in vitro

L. Selth, W. Tilley, T. Hickey, 2019, Oncology Abstracts.

Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.

Sunita K. C. Basnet, Shudong Wang, Malika Kumarasiri, 2015, European journal of medicinal chemistry.

Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.

Shudong Wang, Manjun Li, Mingfeng Yu, 2021, European journal of medicinal chemistry.

Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.

Shudong Wang, N. Portman, Sarah Alexandrou, 2019, Endocrine-related cancer.

Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML

I. Lewis, L. To, Shudong Wang, 2015 .

Substituted 4-(Thiazol-5-Yl)-2-(Phenylamino)Pyrimidines are Highly Active Cdk9 Inhibitors: Synthesis, X-Ray Crystal Structure, Sar and Anti-Cancer Activities.

M. Noble, J. Endicott, P. Fischer, 2013 .

MAP kinase-interacting kinases--emerging targets against cancer.

C. Proud, Shudong Wang, Malika Kumarasiri, 2014, Chemistry & biology.

Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.

Shudong Wang, F. Lam, M. Sykes, 2015, Cancer letters.

Dynamical insights of Mnk2 kinase activation by phosphorylation to facilitate inhibitor discovery.

Shudong Wang, Malika Kumarasiri, Theodosia Teo, 2015, Future medicinal chemistry.

CDKI‐71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol

P. Fischer, Shudong Wang, Xiangrui Liu, 2012, International Journal of Cancer.

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

D. Lane, R. Jackson, D. Zheleva, 2010, Chemistry & biology.

Discovery and Pharmacological Characterisation of a Novel Series of Highly Selective Inhibitors of Cyclin-Dependent Kinases 4 and 6 as Anticancer Agents Running Title Highly Selective CDK 4 / 6 Inhibitors as Anticancer Agents

Shudong Wang, F. Lam, Malika Kumarasiri, 2017 .